Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Neil Kay, MD, Mayo Clinic
Conference Coverage
Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia
02/27/2024

Featuring Neil E. Kay, MD

Featuring Neil E. Kay, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia &...
02/27/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
Analyzing Immunotherapy Options for the Treatment of Patients With Large-Cell Lymphoma
02/26/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.
Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.
Andrew Zelenetz, MD, discusses...
02/26/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Treatment Shows Potential for Patients With Non-GCB DLBCL
02/26/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...
Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...
Andrew Zelenetz, MD, shares...
02/26/2024
Oncology
Ajai Chari, MD
Conference Coverage
Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Komal Jhaveri, MD
Videos
Capivasertib Plus Palbociclib and Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
02/23/2024

Featuring Komal Jhaveri, MD

Featuring Komal Jhaveri, MD
Komal Jhaveri, MD, discusses results from the CAPItello-291 study, which led to the FDA approval of capivasertib plus fulvestrant for HR-positive, HER2-negative, advanced breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.
Komal Jhaveri, MD, discusses results from the CAPItello-291 study, which led to the FDA approval of capivasertib plus fulvestrant for HR-positive, HER2-negative, advanced breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.
Komal Jhaveri, MD, discusses...
02/23/2024
Oncology
Ajai Chari, MD
Conference Coverage
Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer
02/22/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of...
02/22/2024
Oncology
Jie Jin, MD, PhD
Videos
Assessing Efficacy of Jaktinib Among Ruxolitinib-Intolerant Patients With Myelofibrosis
02/21/2024

Featuring Jie Jin, MD, PhD

Featuring Jie Jin, MD, PhD
Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.
Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.
Jie Jin, MD, PhD, shares results...
02/21/2024
Oncology
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer
02/21/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...
In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...
In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...
In this video, our experts...
02/21/2024
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement